By continuing to use Symptoma®, you confirm you accept the cookies. More on
508301 to 508400 most common queries
List represents a sample of symptoms, diseases, and other queries. Updated weekly.
Potential cellular and molecular causes of hypertrophic scar formation.
In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy.
Pericytes as collagen-producing cells in excessive dermal scarring.
Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells.
squeezing pressure tension headache,with burning crawling sensations on scalp
The molecular basis of keloid and hypertrophic scar formation.
Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.
GM-CSF and oncogene mRNA stabilities are independently regulated in trans in a mouse monocytic tumor.
Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis.
Interleukin-induced increase in Ia expression by normal mouse B cells.
Inhibition of macrophage Ca(2+)-independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones.
International clinical recommendations on scar management.
Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids.
The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages.
On the nature of hypertrophic scars and keloids: a review.
Bone marrow-derived stem cells in wound healing: a review.
Macrophages in skin injury and repair.
Expression of programmed death 1 ligands by murine T cells and APC.
Morphological and immunochemical differences between keloid and hypertrophic scar.
Cloning and expression of murine interleukin-1 cDNA in Escherichia coli.
Physiology, pharmacology and plasticity at the inner hair cell synaptic complex.
Guidelines for screening for hearing impairment and middle-ear disorders. Working Group on Acoustic Immittance Measurements and the Committee on Audiologic Evaluation. American Speech-Language-Hearing Association.
Wideband energy reflectance measurements in adults with middle-ear disorders.
Genetic factors in aminoglycoside toxicity.
Clinical, experimental, and theoretical investigations of the effect of superior semicircular canal dehiscence on hearing mechanisms.
Mice overexpressing genes from the 22q11 region deleted in velo-cardio-facial syndrome/DiGeorge syndrome have middle and inner ear defects.
Marine waters contaminated with domestic sewage: nonenteric illnesses associated with bather exposure in the United Kingdom.
Single or multiple daily doses of aminoglycosides: a meta-analysis.
Antimicrobial peptide therapeutics for cystic fibrosis.
Untoward effects associated with practolol administration: oculomucocutaneous syndrome.
A neurophysiological approach to tinnitus: clinical implications.
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
Enhanced Leishmania braziliensis infection following pre-exposure to sandfly saliva.
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.
Reconstitution of the rat olfactory epithelium after methyl bromide-induced lesion.
New hair cells arise from supporting cell conversion in the acoustically damaged chick inner ear.
Connexin disorders of the ear, skin, and lens.
Nuclear-factor kappa B (NF-kappa B)-inducible nitric oxide synthase (iNOS/NOS II) pathway damages the stria vascularis in cisplatin-treated mice.
Myo15 function is distinct from Myo6, Myo7a and pirouette genes in development of cochlear stereocilia.
Age-related cochlear synaptopathy: an early-onset contributor to auditory functional decline.
Hearing loss following Gata3 haploinsufficiency is caused by cochlear disorder.
Effect of protective agents against cisplatin ototoxicity.
The perception of temporal modulations by cochlear implant patients.
Glycine immunoreactivity and receptor binding in the cochlear nucleus of C57BL/6J and CBA/CaJ mice: effects of cochlear impairment and aging.
Significance of spiral ligament fibrocytes with cochlear inflammation.
squeezing pressure tension headache
Selective cochlear degeneration in mice lacking the F-box protein, Fbx2, a glycoprotein-specific ubiquitin ligase subunit.
p27(Kip1) deficiency causes organ of Corti pathology and hearing loss.
Cortical reorganization in patients with high frequency cochlear hearing loss.
Developmental delays consistent with cochlear hypothyroidism contribute to failure to develop hearing in mice lacking Slc26a4/pendrin expression.
A cochlear cell line as an in vitro system for drug ototoxicity screening.
Inherited hearing defects in mice.
Delayed inner ear maturation and neuronal loss in postnatal Igf-1-deficient mice.
Rapid hair cell loss: a mouse model for cochlear lesions.
Sox2 and JAGGED1 expression in normal and drug-damaged adult mouse inner ear.
Spiral ligament pathology: a major aspect of age-related cochlear degeneration in C57BL/6 mice.
Histological classification of ovarian cancer.
Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases.
Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas.
B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease.
Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression.
Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group.
Experience with elemental diet in the treatment of inflammatory bowel disease. Is this primary therapy?
Association of decreased mitochondrial DNA content with ovarian cancer progression.
IGG (7 S GAMMA GLOBULIN) METABOLISM IN HYPOGAMMAGLOBULINEMIA: STUDIES IN PATIENTS WITH DEFECTIVE GAMMA GLOBULIN SYNTHESIS, GASTROINTESTINAL PROTEIN LOSS, OR BOTH.
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages.
Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.
Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors.
Immunoglobulin E in immunologic deficiency diseases. II. Serum IgE concentration of patients with acquired hypogammaglobulinemia, thymoma and hypogammaglobulinemia, myotonic dystrophy, intestinal lymphangiectasia and Wiskott-Aldrich syndrome.
PIK3CA mutations in advanced ovarian carcinomas.
Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection.
IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena.
Five- to fifteen-year follow-up after Fontan operation.
Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease.
Immunoglobulin changes in disease: quantitation on the basis of heavy polypeptide chains, IgG (gammaG), IgA (gammaA), and IgM (gammaM), and of light polypeptide chains, type K (I) and type L (II).
Exudative enteropathy: abnormal permeability of the gastrointestinal tract demonstrable with labelled polyvinylpyrrolidone.
KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.
Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
Histologic types of epithelial ovarian cancer: have they different risk factors?
Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome.
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study.
Neurodevelopment delays in children with deformational plagiocephaly.
Development in toddlers with and without deformational plagiocephaly.
Development at age 36 months in children with deformational plagiocephaly.
Deformational brachycephaly in supine-sleeping infants.
Conservative interventions for positional plagiocephaly: a systematic review.
Neurologic findings in infants with deformational plagiocephaly.
Motor development of infants with positional plagiocephaly.
Management of deformational plagiocephaly: repositioning versus orthotic therapy.
Helmet versus active repositioning for plagiocephaly: a three-dimensional analysis.
Characteristics, head shape measurements and developmental delay in 287 consecutive infants attending a plagiocephaly clinic.
Neurodevelopmental delays in children with deformational plagiocephaly.
[Systematic review of the effects of therapy in infants with the KISS-syndrome (kinetic imbalance due to suboccipital strain)].
Risk factors for deformational plagiocephaly at birth and at 7 weeks of age: a prospective cohort study.